Lankenau Institute for Medical Research

Conformal Medical to Present One-Year Data from its Left Atrial Appendage Occlusion (LAAO) Early Feasibility Study at TCT 2023

Retrieved on:

Thursday, October 19, 2023

Stroke, Medical research, Atrial fibrillation, Ventricular fibrillation, Lankenau Institute for Medical Research, Structure, Conformal, Health, CLAAS, TEE, Anticoagulant, LAA, Risk, EFS, Safety, TCT, Patient, Main Line Health, Medical device

NASHUA, N.H., Oct. 19, 2023 /PRNewswire/ -- Conformal Medical, Inc. announced today the one-year results from the company's CONFORMAL Early Feasibility Study (EFS) will be presented during the 2023 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, CA. Dr. William Gray, System Chief, Cardiovascular Diseases at Main Line Health and professor at Lankenau Institute for Medical Research will present, "Conformal CLAAS LAAO Device EFS 1-Year TEE Follow Up" during a moderated abstract session.

Key Points:

"I look forward to presenting the much anticipated one-year TEE follow up data from our initial clinical experience," stated Dr. Gray.
"We are extremely pleased to have the one-year Conformal EFS data presented at this year's TCT conference," commented James Reinstein, CEO of Conformal Medical.
Conformal Medical is currently enrolling patients in its CONFORM Pivotal Trial to support U.S. commercialization.
Wednesday, October 25th - Conformal Medical to host a breakfast symposium, "CLAAS Act: Conformal Medical Overview and CONFORM Trial Update" at 6:30am PT in Presentation Theater 1.

Virtual Incision Announces MIRA’s Clinical Trial Results Will Be Presented at the 2023 ASCRS Scientific Meeting

Retrieved on:

Wednesday, May 31, 2023

Virtual Incision Corporation , the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will be presented at the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Seattle, WA.

Key Points:

Virtual Incision Corporation , the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will be presented at the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting in Seattle, WA.
The study was designed to evaluate the safety and efficacy of MIRA for use in bowel resection procedures.
John Marks will unveil the full patient data set to his peer group for the very first time,” said John Murphy, president and chief executive officer of Virtual Incision.
Virtual Incision is the first RAS developer to complete a U.S. IDE study to support a De Novo request in bowel resection.

Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

Retrieved on:

Monday, March 6, 2023

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors.

Key Points:

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors.
“We are pleased to expand our cardiovascular leadership as we welcome Jonathan to our Board of Directors,” said Kevin Koch, Ph.D., President and Chief Executive Officer.
Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research.
Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.

Main Line Health researcher releases world's first complete resource on molecular structure of virus that causes COVID-19

Retrieved on:

Thursday, February 16, 2023

Vaccine, SARS-CoV-2, Protein, Lankenau Institute for Medical Research, Genetic code, Molecular biology, Literature, Sunil Thomas, Second Edition, Main Line Health, Medical research, Map, Non-Euclidean geometry, Disease, Infection, Multimedia, Viral, COVID-19, Doctor of Philosophy

WYNNEWOOD, Pa. , Feb. 16, 2023 /PRNewswire/ -- A biomedical researcher at the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, has created a groundbreaking resource for scientists seeking to develop new and better vaccines in the fight against COVID-19.

Key Points:

We will continue to need new vaccines and therapies that are safe and more effective than those available today."
But all the vaccines created targeted the viral spike protein, the part of the virus that binds to human cells.
"Dr. Thomas's efforts to scour the literature and create this open-source compilation of the SARS-CoV-2 molecular structure is an excellent contribution to the scientific community.
The set has reached 120,000 downloads since its January 2022 publication in Springer's Methods in Molecular Biology series.

Main Line Health scientist attracts $1M gift to advance revolutionary research into scarless healing--even for age-associated chronic wounds

Retrieved on:

Thursday, September 15, 2022

MERION STATION, Pa., Sept. 15, 2022 /PRNewswire/ -- Scientists had thought only starfish and amphibians like frogs and salamanders could heal wounds in a way that looked as if the injury never occurred, even regenerating entire limbs. Mammals—including humans—had lost the ability to generate new tissue to evolution.

Key Points:

Her mid-1990s discovery not only sparked hope for human scarless healing but triggered headlines worldwide.
Dr. Heber-Katz was named inaugural chairholder of The Daniel B. and Florence E. Green Endowed Chair in Regenerative Medicine Research last night.
"This gift will accelerate the timetable for testing in humans and, I firmly believe, bring a drug to market," Dr. Heber-Katz said.
Dr. Heber-Katz has two key products near the stage for human testing:
A drug in the form of a hydrogel.

Children's Hospital of Philadelphia and Main Line Health Announce New Affiliation

Retrieved on:

Tuesday, September 13, 2022

PHILADELPHIA, Sept. 13, 2022 /PRNewswire/ -- Today Children's Hospital of Philadelphia (CHOP) and Main Line Health announced an affiliation agreement that will fully transition Main Line Health's pediatric care and services from Nemours Children's Health to CHOP.

Key Points:

PHILADELPHIA, Sept. 13, 2022 /PRNewswire/ -- Today Children's Hospital of Philadelphia (CHOP) and Main Line Health announced an affiliation agreement that will fully transition Main Line Health's pediatric care and services from Nemours Children's Health to CHOP.
Main Line Health and CHOP have already begun to collaborate, utilizing the combined expertise and infrastructure of the two organizations to deliver outstanding and convenient care to patients and families at Main Line Health suburban locations.
In April 2022, CHOP began to provide complex ophthalmic care for premature babies at all four Main Line Health hospitals' NICUs.
Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its western suburbs.

Main Line Health Hospitals Are Top Performers in New Centers for Medicare & Medicaid Services' Ratings

Retrieved on:

Monday, August 15, 2022

All four of Main Line Health's acute care hospitals have been rated as top performers.

Key Points:

All four of Main Line Health's acute care hospitals have been rated as top performers.
Results are based on data from 2020 and 2021, highlighting Main Line Health's commitment to quality and safety during the pandemic.
"This is an incredible achievement but is no surprise," said Jack Lynch, FACHE, President and Chief Executive Officer, Main Line Health.
Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its western suburbs.

Conformal Medical Announces Launch of CONFORM Pivotal Trial

Retrieved on:

Friday, June 17, 2022

NASHUA, N.H., June 17, 2022 /PRNewswire/ -- Conformal Medical, Inc., a medical device company developing next-generation LAAO technology, today announced the launch of the CONFORM pivotal trial with the enrollment of the first patients at two U.S. sites. The investigational device exemption (IDE) study will evaluate the safety and efficacy of the company's CLAAS® System compared to commercially available LAAO devices to support U.S. Food and Drug Administration (FDA) pre-market approval.

Key Points:

NASHUA, N.H., June 17, 2022 /PRNewswire/ -- Conformal Medical, Inc. , a medical device company developing next-generation LAAOtechnology,today announced the launch of the CONFORM pivotal trial with the enrollment of the first patients at two U.S. sites.
"We are pleased to enroll the first patients in the CONFORM trial, an important milestone for the company.
Kicking off the study builds on the strong momentum from our EFS experience," commented Andy Levine, President and CEO of Conformal Medical.
Founded in 2016, Conformal Medical, Inc. is a medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation.

Main Line Health earns 'LGBTQ+ Health Care Equality Top Performer' designation in Human Rights Campaign Foundation's 2022 Healthcare Equality Index

Retrieved on:

Thursday, April 7, 2022

RADNOR, Pa., April 7, 2022 /PRNewswire/ -- Today, Main Line Health announced its Systemwide designation as an "LGBTQ+ Healthcare Equality Top Performer" in the Human Rights Campaign Foundation's 15th anniversary edition of the Healthcare Equality Index (HEI). The HEI is a national benchmarking survey of healthcare facilities on policies and practices dedicated to the equitable treatment and inclusion of their LGBTQ+ patients, visitors, and employees. A record 906 healthcare facilities actively participated in the 2022 HEI survey and 251 of those earned an "LGBTQ+ Healthcare Equality Top Performer" designation.

Key Points:

RADNOR, Pa., April 7, 2022 /PRNewswire/ -- Today, Main Line Health announced its Systemwide designation as an "LGBTQ+ Healthcare Equality Top Performer" in the Human Rights Campaign Foundation's 15th anniversary edition of the Healthcare Equality Index (HEI).
A record 906 healthcare facilities actively participated in the 2022 HEI survey and 251 of those earned an "LGBTQ+ Healthcare Equality Top Performer" designation.
Main Line Health provides a safe environment where LGBTQ+ patients, families and visitors can expect inclusive care.
"Main Line Health is committed to fostering an equitable, inclusive environment so that all will feel seen, welcomed and most importantly receive safe, high quality care," said Jack Lynch, FACHE, president and CEO, Main Line Health.

Main Line Health Hospitals Recognized as a "World's Best" by Newsweek

Retrieved on:

Thursday, March 31, 2022

WYNNEWOOD, Pa., March 31, 2022 /PRNewswire/ -- Lankenau Medical Center , Bryn Mawr Hospital and Paoli Hospital ,part of Main Line Health, were named as one of the "World's Best Hospitals" by Newsweek .

Key Points:

WYNNEWOOD, Pa., March 31, 2022 /PRNewswire/ -- Lankenau Medical Center , Bryn Mawr Hospital and Paoli Hospital ,part of Main Line Health, were named as one of the "World's Best Hospitals" by Newsweek .
Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its western suburbs.
A team of more than 10,000 employees, 3,000 nurses and 2,000 physicians care for patients throughout the Main Line Health System.
Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region's largest multispecialty physician networks.